Status:
COMPLETED
The Optimization of Mycoplasm Pneumonia Antibiotic Therapy
Lead Sponsor:
Capital Medical University
Conditions:
Mycoplasma Pneumonia
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.
Detailed Description
Mycoplasma pneumoniae was one of important atypical pathogens of community acquired pneumonia. As lack of cell wall, β-lactam medicines were invalid, however, macrolides, tetracyclines and quinolones ...
Eligibility Criteria
Inclusion
- Confirmed community acquired pneumonia
- 60ys≥age≥18 ys
- Respiratory symptom (cough accompanied by little or no sputum)
- New infiltration showed by chest radiology(x-ray or CT)
- Lung signs was not obvious
- White blood cell\<10,000/mm3
- Without underlying diseases or mild
Exclusion
- Age\<18ys or \>60ys
- Pregnancy or breast-feeding
- Over one week after the onset of symptoms
- HIV infection
- Recent 90-day hospitalized history(length of stay greater than 2 days)
- Live in nursing homes or rehabilitation hospitals
- Taken macrolides or quinolones medicines before enrollment
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT01259141
Start Date
October 1 2010
End Date
December 1 2014
Last Update
July 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute
Beijing, Beijing Municipality, China, 100020